JOINT PRODUCT DEVELOPMENT Sample Clauses

The Joint Product Development clause establishes the terms under which two or more parties collaborate to design, develop, or improve a product together. It typically outlines each party’s roles, responsibilities, and contributions, such as sharing technical expertise, resources, or intellectual property. This clause ensures that all parties have a clear understanding of how the development process will be managed, how ownership of resulting products or inventions will be handled, and how any resulting profits or rights will be allocated, thereby preventing disputes and promoting effective cooperation.
POPULAR SAMPLE Copied 10 times
JOINT PRODUCT DEVELOPMENT. 3.1 The Parties shall continue to market and sell their vehicles independently and on a competitive basis under their respective brands. With respect to platforms and their components, the Parties shall cooperate on the development of vehicles and their components on shared selected platforms, aiming at the convergence of modules and components, in order to leverage volumes, advance technologies and reduce emissions. 3.2 In order to implement the foregoing, the Parties or their appropriate Affiliates shall enter into: (i) a framework development agreement concerning the development of the Products and the ownership and licensing of Intellectual Property relating to the Products, including the terms (other than industrialization and transfer pricing) set out in Exhibit 2 (the “Development Agreement”): the Parties confirm that the Development Agreement executed by the Parties on the date hereof satisfies entirely the obligations of the Parties under this Section 3.2(i); (ii) supply agreements concerning the supply of the Products, including the terms concerning industrialization and transfer pricing set out in Exhibit 2 (the “Supply Agreements”); and (iii) powertrain supply agreements concerning the supply of engines and transmissions to be installed in the Products, including the terms concerning industrialization and transfer pricing set out in Exhibit 2 (the “Powertrain Supply Agreements”).
View SourceView Similar (2)
JOINT PRODUCT DEVELOPMENT. 3.1 The Parties are interested in investigating a joint development of a new line of products which would combine key elements of Hydrocell's existing technology of tubular shaped 20 Watt modular systems with key elements of MORE's existing technology of proprietary fuel as well as catalytic materials and electrode technology. The performance envelope for such new Products will be no less than 20 Watts and no more than 200 Watts and will be for applic▇▇▇▇▇s in the area of military programs, automotive uses, and stationary power systems. Any marketing or sale for other applications will require the prior written approval of both Parties which they may deny at their sole discretion. The Parties will jointly own the resulting product and they will agree on the commercialization sharing including allocation of markets, cross-licensing terms and royalty terms. Both Party's reserve the right to offer their own products to the above markets in parallel to the new jointly owned Product. It is the intention that in each instance where a party intends to offer its own products as well it will first discuss the situation with the other Party without limiting its absolute discretion to make its own decision. 3.2 The Parties will finalize a Statement of Work and separate agreement for this joint development as soon as practicable. It is assumed that each Party would absorb its own costs in such development effort and would share joint expenses (such as testing). The Parties will make efforts to find customer funding if possible and they will equitably share in any such funding.
View Source
JOINT PRODUCT DEVELOPMENT. 3.1 The Parties shall continue to market and sell their vehicles independently and on a competitive basis under their respective brands. With respect to platforms and their components, the Parties shall cooperate on the development of vehicles and their components on shared selected platforms on a worldwide basis, aiming at the convergence of modules and components, in order to leverage volumes, advance technologies and reduce emissions. 3.2 In order to implement the foregoing, the Parties or their appropriate Affiliates shall enter into: (i) development agreements concerning the development of the Products and the ownership and licensing of Intellectual Property relating to the Products, including the terms (other than industrialization and transfer pricing) set out in Exhibit 2 (the “Development Agreements”); (ii) supply agreements concerning the supply of the Products, including the terms concerning industrialization and transfer pricing set out in Exhibit 2 (the “Supply Agreements”); and (iii) powertrain supply agreements concerning the supply of engines and transmissions to be installed in the Products, including the terms concerning industrialization and transfer pricing set out in Exhibit 2 (the “Powertrain Supply Agreements”).
View Source
JOINT PRODUCT DEVELOPMENT. As may be mutually agreed to from time to time by the parties hereto, IWAV and UTStarcom agree to jointly cooperate in the design and development of products other than the Products, and/or new features for the Products. UTStarcom and IWAV agree that any such joint product development shall be the subject of a separate agreement, the terms and conditions of which to be mutually agreed to by the parties.
View Source
JOINT PRODUCT DEVELOPMENT. Readiness for Phase IIb Development. With respect to any Product that is subject to Joint Development pursuant to Section 5.4(c) above, the JDC for such Product Candidate shall discuss and determine whether the Product Candidate is ready for Phase IIb Clinical Studies, and if not, what additional Development activities are required prior to the conduct of a Phase IIb Clinical Study.
View Source
JOINT PRODUCT DEVELOPMENT. Racom and Rohm agree to cooperate in the development of Ferroelectric RFID Products. Racom's responsibilities shall be the definition, electrical design, marketing and sales. Rohm's responsibilities shall be the physical design, wafer manufacturing and testing. Rohm will have the exclusive manufacturing right for jointly developed products and Racom will have the exclusive marketing and sales rights. Each party will be responsible for funding their own efforts under their respective development responsibilities. After successful completion of development, Racom will order and purchase jointly developed products from Rohm in accordance with Section 5.1. Rohm and Racom agree that the first two designs for joint development are the ▇▇ ▇▇ ASIC and a second HF ASIC both scheduled to complete development by the end of 1996.
View Source
JOINT PRODUCT DEVELOPMENT 
View SourceView Similar (2)

Related to JOINT PRODUCT DEVELOPMENT

  • Product Development (a) Supplier may develop enhancements it intends to incorporate into the BioGlue Surgical Adhesive during the term of this Agreement that have potential application to the Company Product (“Enhancements”). Unless otherwise agreed by the parties, at least once every six months during the Term, representatives of each of BioForm and Supplier shall hold a meeting in accordance with Sections 4.4 and 8.4 (the “Product Development Meeting”) at which Supplier will present Enhancements for BioForm to consider for application to the Company Product. At such Product Development Meeting, BioForm will also present its marketing plans (pursuant to Section 4.4) for the period and any information or feedback that BioForm reasonably believes may lead to Improvements. Within 30 calendar days following each Product Development Meeting, Supplier shall deliver a notice to BioForm (the “Enhancements Notice”) that shall describe the Enhancements that were presented by Supplier at such Product Development Meeting. Within 30 calendar days following receipt of the Enhancements Notice, BioForm may notify Supplier in writing if BioForm elects that any Enhancement described in the Enhancements Notice shall become an Improvement. If BioForm does provide such notice to Supplier during such 30-calendar day period, then BioForm and Supplier shall agree on a timeline for implementation of the Improvement in new Product Specifications for Company Product. If BioForm does not provide such a notice, said Enhancement shall not be implemented into the Company Product. The Enhancements Notice may also describe any potential Enhancements presented by Supplier at the Product Development Meeting, but BioForm shall not be required to take any action under this Section 8.4 with respect to such potential Enhancements until such time as they are presented by Supplier as Enhancements at a future Product Development Meeting. All Enhancements and potential Enhancement information provided by Supplier shall be considered Supplier Confidential Information. (b) From time to time, each party may request the other party to participate in joint projects to develop Improvements. Neither party is obligated to participate in such projects, and in each **** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. instance, each party’s decision whether to participate will be made in such party’s sole discretion. If both parties mutually agree to participate in such a project (a “Program”), the parties will promptly prepare a mutually agreeable written development agreement specifying the development activities to be performed by and the research and development tasks assigned to each party (the “Development Agreement”). All allocation of Intellectual Property rights with respect to any Program will be set forth in writing in the Development Agreement. (c) In the absence of a Development Agreement, (i) BioForm and Supplier shall retain joint ownership of Intellectual Property rights in which there is joint inventorship by BioForm (or its Affiliates) and Supplier, as determined in accordance with United States patent law, with Supplier’s rights in such joint ownership being subject to the license rights of BioForm under this Agreement, (ii) any Intellectual Property rights related to the Company Products, Enhancements, and Improvements that are created solely by employees or consultants of Supplier during the Term shall be considered to be Intellectual Property rights of Supplier, subject to the license rights of BioForm under this Agreement, and (iii) any Intellectual Property rights related to the Company Products and Improvements that are created solely by employees or consultants of BioForm or any of its Affiliates during the Term shall be considered to be Intellectual Property rights of BioForm. BioForm hereby grants to Supplier a perpetual, royalty free, world-wide, nonexclusive license to Supplier under such Blocking Intellectual Property to make, use, and sell such Intellectual Property outside the Field. “Blocking Intellectual Property” for the purposes of Section 8.4(c)(iii) shall mean Intellectual Property necessary for Supplier to make, use, or sell SA Product.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Primary Investigator as part of a multi-site study (25 points) • Co-Investigator as part of a multi-site study (20 points) • Primary Investigator of a facility/unit based research study (15 points) • Co-Investigator of a facility/unit based research study (10 points) • Develops a unit specific research proposal (5 points) • Conducts a literature review as part of a research study (5 points)

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.